Certification ensures highest level of patient data security a medical device can attain
TELFORD, Pa., Aug. 11, 2025 /PRNewswire/ — Today Dräger, an international leader in medical and safety technologies, announced that the company’s Atlan A350/A350 XL series of anesthesia workstations received Authority to Operate (ATO) certification under the Department of Defense’s (DoD) Risk Management Framework (RMF) eMASS #4060.
“Cyberattacks continue to be a serious threat to hospitals – both clinically and financially,” said President and CEO for Draeger, Inc., Lothar Thielen. “To help hospitals meet this challenge, Dräger embeds the latest cybersecurity technology deeply into our development processes. Our new Atlan anesthesia workstations now carry ATO certification, which is the highest level of security a medical device can hold.”
Continuing a longstanding commitment to patient data security
Certification of Dräger’s Atlan A350/A350XL anesthesia workstation follows the certifications of the Perseus A500 (eMASS # 2852) and Fabius MRI (eMASS # 2875) anesthesia workstations. Now with the Atlan certification, Dräger anesthesia customers can have confidence knowing that Dräger’s entire anesthesia machine portfolio has gone through this rigorous cyber-security review process.
Benefits of ATO-certified medical devices
Medical devices that have achieved an Authority to Operate (ATO) under the Risk Management Framework (RMF) offer significant advantages to hospitals, including:
These benefits enable ATO-certified medical devices to provide stronger patient data protection and carry a lower risk of cyberattacks.
More information:
Dräger Atlan A350/A350 XL family of devices:
https://www.draeger.com/en-us_us/Products/Atlan-A350-US-Version
You can find more information and pictures in our press center:
https://www.draeger.com/en-us_us/Newsroom/Press-Center
Dräger. Technology for Life.
Dräger is a leading international medical and safety technology company. Our products protect, support and save lives. Founded in Lübeck, Germany in 1889, Dräger generated global sales of around EUR 3,4 billion in 2024. The Lübeck-based company is represented in more than 190 countries and employs more than 16,000 people worldwide. For more information, visit www.draeger.com
Contact
Communications: Melanie Kamann, Tel. +49 451 882-3202, melanie.kamann@draeger.com
Press Contact North America: Laura Edwards, Tel. +1 215 565-5868, laura.edwards@draeger.com
Investor Relations: Thomas Fischler, Tel. +49 451 882-2685, thomas.fischler@draeger.com
SOURCE Draeger
Telehealth Provider Offers FDA-Approved and Compounded Weight Loss Medications in All 50 States, Subject to…
Telehealth Platform Facilitates Compounded Semaglutide and Tirzepatide Access Through Licensed Provider Evaluation as FDA Shortage…
Analysis examines best peptides for boosting growth hormone as ReadyRx lists prescription sermorelin in injectable…
Discover the best fat burner for men in 2025. Explore Wolfson Brand’s effective fat-burning supplements…
Industry Analysis Examines How Cost, Safety, and Access Considerations Shape Semaglutide Choices as MEDVi Lists…
Deploying “Proof of Human” Infrastructure throughout Japan, a Technology Envisioned by Sam Altman and Alex…